Fractyl Health will advance its Revita therapy toward an FDA De Novo submission based on positive clinical data while discontinuing its Rejuva gene therapy. This strategic shift includes a workforce reduction to extend cash runway into 2027.
Fractyl Health will advance its Revita therapy toward an FDA De Novo submission based on positive clinical data while discontinuing its Rejuva gene therapy. This strategic shift includes a workforce reduction to extend cash runway into 2027.